Periosteal Chondrosarcoma: a Single Institution Experience

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

55 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-04-01

Study Completion Date

2021-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Periosteal chondrosarcoma is a low-grade, malignant cartilaginous bone neoplasm that arises on the surface of bone, predominantly in the metaphysis of long bones.

Periosteal chondrosarcoma is an infrequent chondrosarcoma subtype which accounts for less than 1% of all chondrosarcomas (1) and has a peak incidence in the fourth decade (2).

It has a reported incidence of local recurrences of 13-28% and a low metastatic potential, with distant recurrences occurring mostly in lungs (3).

Contrary to conventional chondrosarcomas, grading of periosteal chondrosarcomas seems not to predict prognosis. IDH1 and IDH2 mutations, characteristics of central chondromas/chondrosarcomas, have been also found in a subset of periosteal chondrosarcomas (1, 4).

These observations are based on the results from smaller series of cases (1, 5, 6), although the impact of histopathological characteristics on survival, local recurrence and metastases should be assessed in larger series of cases.

The aim of the present study is to review all the cases with a diagnosis of primary periosteal chondrosarcoma treated at the Rizzoli Institute from 1900 up to 31 December 2019, retrospectively.

The study will exam all the clinical, radiological, and histological features of this tumor with regard importance of medullary involvement, the IDH1/2 gene status, the types of treatment, the status of surgical margins, the presence of progression (dedifferentiation) areas and the relationship of these factors to individual outcome.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Incisional Biopsy Versus Core-needle Biopsy in Bone Tumors Analysis

NCT07113301

Malignant Bone Tumor

ACTIVE_NOT_RECRUITING

US-Guided Biopsy in the Diagnosis of Musculoskeletal Soft-Tissue Tumors

NCT03452644

Soft Tissue Neoplasm Soft Tissue Sarcoma Soft Tissue Mass +1 more

COMPLETED

CT Scan Guide Percutaneous Biopsy of Lytic Bone Metastases of Lung Cancer : Contribution in Pathology Diagnosis and Molecular Biology

NCT03386916

Image-Guided Biopsy - Carcinoma, Bronchogenic / Diagnosis- Outpatients

UNKNOWN

Magnetic Resonance Imaging or Ultrasound in Soft Tissue Tumors (MUSTT)

NCT02834585

Sarcoma Soft Tissue Tumors Ultrasound +5 more

UNKNOWN

Rapid On-site Cytopathologic Evaluation in the Diagnosis of Hilar/Mediastinal Adenopathy

NCT00915330

Lung Cancer Sarcoidosis Tuberculosis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Periosteal Chondrosarcoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female patients treated at Rizzoli Institute from 01 Jan 1900 to 31 Dec 2019
* Diagnosis of peristeal chondrosarcoma
* Written informed consent prior to any study-specific analysis and/or data collection